- Home
- Equipment
- switzerland
- targeted boron drugs
Refine by
Targeted Boron Drugs Equipment Supplied In Switzerland
8 equipment items found
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for [18F]-choline (FCH). ...
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for 6-fluoro-[18F]-L-DOPA, a DOPA analog. Neurology, ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, GPCRs whose natural ligands are large peptides or small proteins are ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that may offer a competitive advantage over classical ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, ...
Manufactured by:InterAx Biotech AG based inVilligen, SWITZERLAND
Our breakthrough platform combines systems biology, pharmacology, and artificial intelligence to accelerate the hit-to-lead process in GPCR drug discovery. InterAx is setting an industry example of how to better understand the biology of a disease and de-risk drug candidates. Instead of only leveraging large quantities of data with machine learning algorithms, we simultaneously incorporate ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based ...